

Julie R Gralow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9018543/publications.pdf>

Version: 2024-02-01

78
papers

6,004
citations

147726

31
h-index

79644

73
g-index

79
all docs

79
docs citations

79
times ranked

7533
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 32-42.	1.1	4
2	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441.	1.4	16
3	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617.	3.2	4
4	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
5	Cancer research collaboration between the UK and the USA: reflections on the 2021 G20 Summit announcement. <i>Lancet Oncology</i> , The, 2022, 23, 460-462.	5.1	5
6	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.	0.8	68
7	Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trialsâ€“Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop. <i>JCO Global Oncology</i> , 2022, , .	0.8	2
8	Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18807-e18807.	0.8	0
9	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63.	3.0	98
10	¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2â€“ Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	2.8	20
11	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021, 29, 2509-2517.	1.0	17
12	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
13	When cardiomyopathy, cancer, and COVIDâ€“19 collide: A case report. <i>Breast Journal</i> , 2021, 27, 384-386.	0.4	0
14	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2021, 113, 989-996.	3.0	13
15	Advancing Breast Cancer Advocacy in Eastern Europe and Central Asia: Findings From Womenâ€™s Empowerment Cancer Advocacy Network (WE CAN) Summits. <i>JCO Global Oncology</i> , 2021, 7, 585-592.	0.8	2
16	Time to Focus on Breast Cancer in Young Adults. <i>JCO Oncology Practice</i> , 2021, 17, 314-316.	1.4	1
17	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
18	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	3.2	9

#	ARTICLE	IF	CITATIONS
19	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
20	Couple Communication in Cancer: Protocol for a Multi-Method Examination. <i>Frontiers in Psychology</i> , 2021, 12, 769407.	1.1	9
21	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	3.0	48
22	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	3.4	51
23	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020, 38, 804-814.	0.8	142
24	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. <i>Journal of Clinical Oncology</i> , 2020, 38, 2122-2129.	0.8	59
25	Breast cancer patient advocacy: A qualitative study of the challenges and opportunities for civil society organizations in low-income and middle-income countries. <i>Cancer</i> , 2020, 126, 2439-2447.	2.0	6
26	Resource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 217-226.	1.8	3
27	The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource-Stratified Phased Implementation: Methods and overview. <i>Cancer</i> , 2020, 126, 2339-2352.	2.0	54
28	The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 6.	2.3	26
29	Patient Advocacy Approaches to Improving Care for Breast and Cervical Cancer in East and Southern Africa. <i>JCO Global Oncology</i> , 2020, 6, 49-55.	0.8	4
30	Breast cancer treatment: A phased approach to implementation. <i>Cancer</i> , 2020, 126, 2365-2378.	2.0	74
31	Recommendations from the ASCO Academic Global Oncology Task Force. <i>JCO Global Oncology</i> , 2020, 6, 1666-1673.	0.8	8
32	Evaluating the Effect of a Video Education Curriculum for First Time Breast Cancer Patients: a Prospective RCT Feasibility Study. <i>Journal of Cancer Education</i> , 2019, 34, 1234-1240.	0.6	9
33	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1226-1234.	13.9	95
34	Role of Family Obligation Stress on Ugandan Women's Participation in Preventive Breast Health. <i>Oncologist</i> , 2019, 24, 624-631.	1.9	9
35	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. <i>Clinical Breast Cancer</i> , 2019, 19, e283-e296.	1.1	24
36	Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). <i>Breast</i> , 2018, 39, 131-138.	0.9	167

#	ARTICLE	IF	CITATIONS
37	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e143-e149.	1.1	15
38	ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
39	Breast Cancer Beliefs as Potential Targets for Breast Cancer Awareness Efforts to Decrease Late-Stage Presentation in Uganda. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	10
40	Links Between Communication and Relationship Satisfaction Among Patients With Cancer and Their Spouses: Results of a Fourteen-Day Smartphone-Based Ecological Momentary Assessment Study. <i>Frontiers in Psychology</i> , 2018, 9, 1843.	1.1	36
41	Prospective Study of Serial ¹⁸ F-FDG PET and ¹⁸ F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1823-1830.	2.8	41
42	Resource-stratified implementation of a community-based breast cancer management programme in Peru. <i>Lancet Oncology</i> , The, 2017, 18, e607-e617.	5.1	25
43	Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq1 1 0.784314 rgBT C	1.0	18
44	Hot flashes in breast cancer survivors: Frequency, severity and impact. <i>Breast</i> , 2016, 27, 116-121.	0.9	45
45	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	13.9	507
46	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , 2016, 34, 699-705.	0.8	42
47	Screening MRI in Women With a Personal History of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv349.	3.0	118
48	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. <i>Journal of Clinical Oncology</i> , 2015, 33, 1910-1917.	0.8	83
49	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
50	Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. <i>BMC Cancer</i> , 2015, 15, 535.	1.1	11
51	SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 58-64.	0.8	89
52	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015, 33, 503-503.	0.8	16
53	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	0.8	771
54	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210

#	ARTICLE	IF	CITATIONS
55	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	0.8	543
56	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.. <i>Journal of Clinical Oncology</i> , 2014, 32, 558-558.	0.8	12
57	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013, 137, 903-913.	1.1	31
58	The importance of survivors and partners in improving breast cancer outcomes in Uganda. <i>Breast</i> , 2013, 22, 138-141.	0.9	21
59	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast) <i>Tj ETQq1 1 0.784314 rgBT /Over to Oncology, The</i> , 2012, 13, 734-742.	5.1	168
60	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 435-444.	13.9	352
61	Can bone-targeted therapy reduce recurrence and improve survival in early-stage breast cancer?. <i>Oncology</i> , 2012, 26, 969-70.	0.4	1
62	Bone Disease in Breast Cancer: The Era of New Targeted Therapies. <i>Current Breast Cancer Reports</i> , 2010, 2, 25-31.	0.5	0
63	Breast cancer advocacy: changing perceptions. <i>Salud Publica De Mexico</i> , 2009, 51, s323-s328.	0.1	10
64	Novel Taxane Formulations in the Treatment of Breast Cancer: A Thought Leader Discussion and Consensus Roundtable. <i>Clinical Breast Cancer</i> , 2008, 8, 33-37.	1.1	14
65	Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screeningâ€™ A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2008, 26, 313-325.	0.8	79
66	Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 814-819.	0.8	352
67	Managing Metastatic Bone Pain: The Role of Bisphosphonates. <i>Journal of Pain and Symptom Management</i> , 2007, 33, 462-472.	0.6	96
68	Breast cancer 2004: Progress and promise on the clinical front. <i>Physica Medica</i> , 2006, 21, 2.	0.4	8
69	Optimizing the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S9-S15.	1.1	64
70	Evolving Role of Bisphosphonates in Women Undergoing Treatment for Localized and Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 5, S54-S62.	1.1	12
71	University of Washington High-Dose Cyclophosphamide, Mitoxantrone, and Etoposide Experience in Metastatic Breast Cancer: Unexpected Cardiac Toxicity. <i>Journal of Clinical Oncology</i> , 2001, 19, 3903-3904.	0.8	3
72	The role of bisphosphonates as adjuvant therapy for breast cancer. <i>Current Oncology Reports</i> , 2001, 3, 506-515.	1.8	3

#	ARTICLE	IF	CITATIONS
73	Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. <i>Cancer</i> , 2001, 92, 720-729.	2.0	234
74	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. , 1999, 85, 2410-2423.		107
75	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. , 1999, 85, 2410.		1
76	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. <i>Cancer</i> , 1999, 85, 2410-2423.	2.0	6
77	Immunity to Oncogenic Proteins. <i>Immunological Reviews</i> , 1995, 145, 33-59.	2.8	167
78	Immunity to the <i>HER2/neu</i> Oncogenic Protein. <i>Novartis Foundation Symposium</i> , 1994, 187, 198-211.	1.2	7